Invitation to presentation of BioInvent’s Year-end report 2020

Lund, Sweden, February 23, 2021BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) invites to a presentation of the Year-end report 2020 and a telephone conference with CEO Martin Welschof and members of the management team. The presentation will be held in English.

When: 3:00 p.m. CET Tuesday February 23, 2021.

Listen to the presentation: https://tv.streamfabriken.com/bioinvent-q4-2020   

To participate in the telephone conference, please use the dial-in details shown below:

SE: +46850558365
NE: +31107129163
UK: +443333009260
US:18335268381

The conference call will be made available on the company’s website after the call.

About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations                Mary-Ann Chang, LifeSci Advisors
+46 (0)46 286 85 50                                      +44 7483 284 853

cecilia.hofvander@bioinvent.com              mchang@lifesciadvisors.com

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50

www.bioinvent.com

About Us

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with four programs in clinical development. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.